Omnigene Medical Technologies Profile

We are excited to announce our success to innovate test-based programs utilising the CE-IVD Dysbiosis test for inflammatory bowel disease (GA-map).  In addition, we licensed-in intellectual property and secured freedom-to-operate in Europe for the first multiplex assay to classify breast cancer.   Ongoing projects include the M3 Profiler aiming to characterise exosomes in cancer patients,  and the upcoming launch of Lifestyle medicine clinics in collaboration with our local and international partners.  We have aligned with European associations and commercial entities to align our programs and research into innovative products.

Join us in our mission:

• An RUO molecular classification of breast cancer is now approved for sale in Europe.
• Prevention of colorectal cancer is also high on our agenda.  Learn more about the Gut restore program as an actionable tool to reduce intestinal inflammation. 
• Our R&D embarked on setting up sensitive techniques to measure biomarkers in blood-derived exosomes.
• Our professional team is seeking partnerships to enhance market entry and develop new products. 
• Our commercial team is providing high quality reagents for research institutions, including cutting edge technologies and services.

REGISTER here to learn more about our products and services.